Alle Storys
Folgen
Keine Story von Sartorius AG mehr verpassen.

Sartorius AG

euro adhoc: Sartorius AG
Financial Figures/Balance Sheet
Preliminary Figures for Fiscal 2005

  Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
02.02.2006
Group earnings (EBIT) improved by 34.3% / Earnings per share up  from
EUR0.89 to EUR1.30 / Sales revenue up 3.6% / Order intake up 7.7% /
Profitable growth expected to be continued in 2006
In fiscal 2005, the Sartorius Group boosted earnings before interest,
taxes, depreciation and amortization (EBITDA) 14.1% from EUR54.8
million to EUR62.5 million. Earnings before interest and taxes (EBIT)
reached EUR43.7 million and were thus 34.3% above the year-earlier
figure (EUR32.5 mn). This corresponds to an EBIT margin of 9.0%
(previous year: 7.0%). For the Biotechnology Division, EBIT was
EUR24.3 million (EUR17.5 mn); for the Mechatronics Division, EUR19.4
million (EUR15.0 mn).
As goodwill amortization ceased to be applied (EUR2.4 mn), this had a
positive impact on EBIT. Expenses for derivative financial
instruments had a negative impact in a similar amount on the
financial result. Net profit surged 45.1% to EUR22.1 million (EUR15.2
mn); earnings per share climbed from EUR0.89 to EUR1.30.
Group sales revenue rose 3.6% (currency adjusted: +3.5%) to EUR484.3
million (EUR467.6 mn). The Biotechnology Division posted a 4.3%
increase in sales revenue to EUR249.8 million (EUR239.4 mn); the
Mechatronics Division, 2.8% to EUR234.5 million (EUR228.1 mn).
Consolidated order intake grew 7.7% (currency adjusted: +7.7%) to
EUR497.0 million (EUR461.6 mn).
The considerably positive net cash flow of EUR33.0 million (EUR36.3
mn) was primarily used to reduce net debt by EUR18.1 million to
EUR60.7 million.
In fiscal 2006, Sartorius is striving to continue profitable growth
and, on the basis of constant currencies, assumes that it will
achieve an increase in sales revenue of over 5%. In addition, the
company intends to raise EBIT to approx. 10% of consolidated sales
revenue.
The figures stated above are still subject to the auditors' final
review. The final numbers will be published at the annual press
conference, which has been moved up to March 14, 2006.
end of announcement                               euro adhoc 02.02.2006 20:07:37

Further inquiry note:

Andreas Wiederhold
Phone +49.551.308.1668
andreas.wiederhold@sartorius.com

Branche: Biotechnology
ISIN: DE0007165607
WKN: 716560
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Frankfurter Wertpapierbörse / official dealing/prime standard
Börse Berlin-Bremen / free trade
Hamburger Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Bayerische Börse / free trade
Niedersächsische Börse zu Hannover / official dealing

Weitere Storys: Sartorius AG
Weitere Storys: Sartorius AG